New and extended-action treatments in the management of ADHD: a critical appraisal of lisdexamfetamine in adults and children

Diana Domnitei, Vishal MadaanDepartment of Psychiatry, Creighton University Medical Center, Omaha, NE, USAAbstract: Treatment guidelines from the American Academy of Child and Adolescent Psychiatry and the American Academy of Pediatrics state that stimulant medications have the most evidence for saf...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Diana Domnitei, Vishal Madaan
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/76a7b95d9d09471b84ee133aa3c5f411
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:76a7b95d9d09471b84ee133aa3c5f411
record_format	dspace
spelling	oai:doaj.org-article:76a7b95d9d09471b84ee133aa3c5f4112021-12-02T02:34:00ZNew and extended-action treatments in the management of ADHD: a critical appraisal of lisdexamfetamine in adults and children1176-63281178-2021https://doaj.org/article/76a7b95d9d09471b84ee133aa3c5f4112010-05-01T00:00:00Zhttp://www.dovepress.com/new-and-extended-action-treatments-in-the-management-of-adhd-a-critica-a4457https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Diana Domnitei, Vishal MadaanDepartment of Psychiatry, Creighton University Medical Center, Omaha, NE, USAAbstract: Treatment guidelines from the American Academy of Child and Adolescent Psychiatry and the American Academy of Pediatrics state that stimulant medications have the most evidence for safety and efficacy in the treatment of childhood attention deficit hyperactivity disorder (ADHD). Longer-acting stimulants are thus considered as first-line for management of ADHD symptoms. Over the years, concerns about the abuse potential of stimulants have led to the development of alternative formulations of these agents. One such recent development, lisdexamfetamine (LDX) was FDA approved for treating ADHD in children in early 2007 and in adults in early 2008. LDX is a prodrug, which when orally ingested, is converted to l-lysine and active d-amphetamine, which is responsible for its therapeutic activity. This unique formulation may lead to a possible reduction of the abuse potential, by bypassing the first-pass metabolism. In fact, a statistically significant difference for the &lsquo;liking&rsquo; effects on the Drug Questionnaire Response has been reported with intravenous LDX compared to d-amphetamine. LDX appears to have an efficacy and tolerability profile comparable to other extended-release stimulant formulations used to treat ADHD, but reduced potential for abuse-related liking effects when compared to equivalent amounts of immediate-release d-amphetamine. The most common adverse events include decreased appetite, insomnia, upper abdominal pain, headache, irritability, weight loss, and nausea.Keywords: lisdexamfetamine, attention deficit hyperactivity disorder, adults, children Diana DomniteiVishal MadaanDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2010, Iss Issue 1, Pp 273-279 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Diana Domnitei Vishal Madaan New and extended-action treatments in the management of ADHD: a critical appraisal of lisdexamfetamine in adults and children
description	Diana Domnitei, Vishal MadaanDepartment of Psychiatry, Creighton University Medical Center, Omaha, NE, USAAbstract: Treatment guidelines from the American Academy of Child and Adolescent Psychiatry and the American Academy of Pediatrics state that stimulant medications have the most evidence for safety and efficacy in the treatment of childhood attention deficit hyperactivity disorder (ADHD). Longer-acting stimulants are thus considered as first-line for management of ADHD symptoms. Over the years, concerns about the abuse potential of stimulants have led to the development of alternative formulations of these agents. One such recent development, lisdexamfetamine (LDX) was FDA approved for treating ADHD in children in early 2007 and in adults in early 2008. LDX is a prodrug, which when orally ingested, is converted to l-lysine and active d-amphetamine, which is responsible for its therapeutic activity. This unique formulation may lead to a possible reduction of the abuse potential, by bypassing the first-pass metabolism. In fact, a statistically significant difference for the &lsquo;liking&rsquo; effects on the Drug Questionnaire Response has been reported with intravenous LDX compared to d-amphetamine. LDX appears to have an efficacy and tolerability profile comparable to other extended-release stimulant formulations used to treat ADHD, but reduced potential for abuse-related liking effects when compared to equivalent amounts of immediate-release d-amphetamine. The most common adverse events include decreased appetite, insomnia, upper abdominal pain, headache, irritability, weight loss, and nausea.Keywords: lisdexamfetamine, attention deficit hyperactivity disorder, adults, children
format	article
author	Diana Domnitei Vishal Madaan
author_facet	Diana Domnitei Vishal Madaan
author_sort	Diana Domnitei
title	New and extended-action treatments in the management of ADHD: a critical appraisal of lisdexamfetamine in adults and children
title_short	New and extended-action treatments in the management of ADHD: a critical appraisal of lisdexamfetamine in adults and children
title_full	New and extended-action treatments in the management of ADHD: a critical appraisal of lisdexamfetamine in adults and children
title_fullStr	New and extended-action treatments in the management of ADHD: a critical appraisal of lisdexamfetamine in adults and children
title_full_unstemmed	New and extended-action treatments in the management of ADHD: a critical appraisal of lisdexamfetamine in adults and children
title_sort	new and extended-action treatments in the management of adhd: a critical appraisal of lisdexamfetamine in adults and children
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/76a7b95d9d09471b84ee133aa3c5f411
work_keys_str_mv	AT dianadomnitei newandextendedactiontreatmentsinthemanagementofadhdacriticalappraisaloflisdexamfetamineinadultsandchildren AT vishalmadaan newandextendedactiontreatmentsinthemanagementofadhdacriticalappraisaloflisdexamfetamineinadultsandchildren
_version_	1718402415567306752

New and extended-action treatments in the management of ADHD: a critical appraisal of lisdexamfetamine in adults and children

Ejemplares similares